Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. (ARTV) reported that entities affiliated with RA Capital received an indirect interest in a stock option for 13,750 shares of Common Stock, granted to director Laura Stoppel on September 8, 2026 under the company’s non-employee director compensation policy at an exercise price of $10.88 per share. The option vests on the earlier of September 8, 2027 or the date of Artiva’s 2027 annual stockholder meeting, and expires on September 7, 2036, subject to Dr. Stoppel’s continuous service as a director. Under Dr. Stoppel’s arrangement with RA Capital’s adviser, any net cash or stock from exercising the option will benefit RA Capital funds and a separately managed account, and the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest; no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 13,750 stock options on September 8, 2026. These options have an exercise price of $10.88 per share and become fully vested on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. The options expire on September 7, 2036, and no Rule 10b5-1 trading plan is reported for this grant.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a grant of 13,750 director stock options on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036. According to the award terms, all shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. Following this grant, Sorg holds 13,750 options directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 13,750 Director Stock Options on September 8, 2026. The options have an exercise price of $10.88 per share and will vest in full on the earlier of September 8, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 13,750 options directly, expiring on September 7, 2036; no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Brian Daniels received a grant of options to purchase 13,750 shares of Common Stock on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036.
These options will vest in full on the earlier of September 8, 2027, or the date of Artiva’s 2027 annual stockholder meeting, and Daniels now holds 13,750 option shares directly after this grant. No Rule 10b5-1 trading plan is reported for this award.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option award for 13,750 shares of common stock on September 8, 2026. The option has an exercise price of $10.88 per share and expires on September 7, 2036.
The option vests in full on the earlier of September 8, 2027 or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, and following this grant Baker holds 13,750 option shares directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of 13,750 stock options on September 8, 2026. The options have an exercise price of $10.88 per share, expire on September 7, 2036, and vest in full on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. No Rule 10b5-1 trading plan is reported for this grant.
Artiva Biotherapeutics, Inc. (ARTV) received a notice that Fred Aslan intends to sell 23,429 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with a stated aggregate market value of $262,170.51 as of September 8, 2026. The shares derive from restricted stock units that vested between May 15, 2025 and September 1, 2026. Over the prior three months, the same person reported selling 61,888 shares of Artiva common stock for $690,391.58.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Tech Operations Officer Christopher Horan sold 10,366 shares of common stock on September 3, 2026, at a weighted average price of $11.1555 per share. According to the company’s sell-to-cover policy, these automatic sales were made solely to satisfy tax withholding obligations from vesting restricted stock units, and Horan held 283,084 shares directly after the transaction.
Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, the company's COO, CLO and Compliance Officer, sold 8,391 shares of common stock on September 3, 2026. The company states these sales were automatic sell-to-cover transactions for tax withholding on vesting restricted stock units, not discretionary trades, leaving her with 329,529 shares held directly.